Subs	titute for form 1449A/PTO				Complete if Known
				Application Number	09/724,319
	FORMATION DIO			Filing Date	November 27, 2000
	FORMATION DISC			First Named Inventor	Schenk, Dale B.
5	TATEMENT BY AF	'PLI	CANI	Art Unit	1649
	(Use as many sheets as ne	cessar	y)	Examiner Name	Ballard, Kimberly
Sheet	1	of	2	Attorney Docket Number	15270J-004743US

			U.S. PATENT DO	CUMENTS	
Examiner Initials*	Cite No.	Document Number Number Kind Code ^{2 (Fixtows)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	892	6,923,964	08-02-2005	Schenk	

				FOREIGN I	PATENT DOCU	MENTS		
Examiner Initials*			Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages			
miliais		Country Code ³	Number ⁴	Kind Code ⁵ (if known)		Applicant of Cited Document	or Relevant Figures Appear	T
*								
								П

Examiner	Date	
Signature	Considered	

EXAMINENT intel if interrise consistent, which or no clastion is in conformance with MPEP 099. Draw line through clastion if not in conformance by the conformance of the conformance of

Substitute fo	or form 1449B/PTO				Complete if Known
				Application Number	09/724,319
INFO	RMATION DIS	CLOS	URE	Filing Date	November 27, 2000
STAT	EMENT BY A	PPLIC	ANT	First Named Inventor	Schenk, Dale B.
				Art Unit	1649
P	Use as many sheets as r	ecessary)		Examiner Name	Ballard, Kimberly
Sheet	2	of	2	Attorney Docket Number	15270J-004743US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	898	ASKELOF et al., "Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella perfussis toxin subunit S1," PNAS, 87:1347-1351 (1990).	
	891	CASADESUS et al., "The Estrogen Myth: Potential Use of Gonadotropin-Releasing Hormone Agonists for the Treatment of Alzheimer's Disease," Drugs R.D. , 7(3):187-193 (2006).	
	893	DE LA CRUZ et al, "Immumogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," <u>J Biol Chem</u> , 263(9):4318-4322 (1988).	
	896	GROSS et al., "Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius," <u>Am J Physiol Regul Intear Comp Physiol</u> , 259:R1131-R1138 (1990).	
	895	KHATOON et al., "Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer's disease and control brains," <u>FEBS Letters</u> , 351:80-84 (1994).	
	889	LIU et al., "Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis," <u>Proc.</u> Natl. Acad. Sci., 95:13266-13271 (1998).	
	890	PEREZ et al., "The β-Amyloid Precursor Protein of Alzheimer's Disease Enhances Neuron Viability and Modulates Neuronal Polarity," <u>J. Neurosci.</u> , 17(24):9407-9414 (1997).	
	897	WHITCOMB et al., "Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain," Am J Pysiol Gastrointest Liver Physiol, 259:G687-G691 (1990).	
	894	WU et al., "Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of Salmonella," <u>PNAS</u> , 86:4726-4730 (1989).	

|--|

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicants using existent designation number (optional). Applicant is to place a check mark here if English language Translation is attached.